Jorge R Miranda-Massari, Alondra P Toro, Doris Loh, Jose R Rodriguez, Raul Morales Borges, Victor Marcial-Vega, Jose Olalde, Miguel J Berdiel, Neil H Riordan, Juan Manuel Martinez, Armando Gil, Michael J Gonzalez
PMID: 34947872 PMCID: PMC8708699 DOI: 10.3390/life11121341
Currently available anti-viral drugs may be useful in reducing the viral load but are not providing the necessary physiological effects to reduce the SARS-CoV-2 complications efficiently. Treatments that provide better clinical outcomes are urgently needed. Vitamin C (ascorbic acid, AA) is an essential nutrient with many biological roles that have been proven to play an important part in immune function; it serves as an antioxidant, an anti-viral, and exerts anti-thrombotic effects among many other physiological benefits. Research has proven that AA at pharmacological doses can be beneficial to patients with acute respiratory distress syndrome (ARDS) and other respiratory illnesses, including sepsis. In addition, High-Dose Intravenous Vitamin C (HDIVC) has proven to be effective in patients with different viral diseases, such as influenza, chikungunya, Zika, and dengue. Moreover, HDIVC has been demonstrated to be very safe. Regarding COVID-19, vitamin C can suppress the cytokine storm, reduce thrombotic complications, and diminish alveolar and vascular damage, among other benefits. Due to these reasons, the use of HDIVC should be seriously considered in complicated COVID-19 patients. In this article, we will emphasize vitamin C’s multiple roles in the most prominent pathophysiological processes presented by the COVID-19 disease.
Keywords: COVID-19, Sars-Cov-2, ascorbic acid, intravenous vitamin C, pathophysiology of COVID-19